Julie Poteet, OD, MS, CNS, FONS, says that a new FDA-approved therapy, photobiomodulation, for treating dry aged-related macular degeneration (AMD), could be a game-changer for optometrists and patients. For those with a family history of AMD, the implications of this new therapy are especially important. Genetic predisposition plays a role, but environmental factors can influence whether those genes lead to disease. If research continues to support photobiomodulation’s effectiveness, Dr. Poteet believes it could become a critical early intervention tool, helping to preserve vision before irreversible damage occurs.